Infliximab
1 NDC across 1 manufacturer|0 Generic,1 Brand
Infliximab is used to treat psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, crohn disease and ankylosing spondylitis, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
In 2024, Medicare Part D spent $122 million on Infliximab across 19,000 claims for 3,580 beneficiaries.
Infliximab is available as 1 NDC from 1 manufacturer (0 generic, 1 brand), with NADAC prices from $1135.97 to $1135.97 per EA. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
1
0G / 1B
Manufacturers
1
competing in market
Price Spread
$1135.97 – $1135.97
per EA
7d Activity
avg +0.0% WoW · of 1 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Manufacturer Breakdown
1 manufacturer producing INFLIXIMAB
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
REMICADE 100 MG VIAL | $1135.9660 per EA | — |
Frequently Asked Questions
What is Infliximab used to treat?
Infliximab is used to treat psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, crohn disease and ankylosing spondylitis, per the National Library of Medicine's MED-RT classification.
How much does Medicare spend on Infliximab?
In 2024, Medicare Part D spent $122 million on Infliximab across 19,000 claims for 3,580 beneficiaries.
How many Infliximab products are on the market?
The Infliximab drug market contains 1 NDC from 1 manufacturer — 0 generic and 1 brand product.
What is the price range for Infliximab?
NADAC reference prices for Infliximab range from $1135.9660 to $1135.9660 per EA.
Which manufacturers make Infliximab?
1 manufacturer lists Infliximab in NADAC. Ranked by number of NDCs, the largest are Janssen Biotech, Inc. (1).